stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Book value per share
Beam Therapeutics Inc.'s book value per share at the end of fiscal 2025 was 12.5×, up 40.5% from 8.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 9.1×. Over the past ten years it has ranged from −40.6× (fiscal 2018) to 12.9× (fiscal 2021); the current reading is higher than 78% of that period. Beam Therapeutics Inc. ranks 82nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 12.5× | 40.50% |
| FY2024 | 8.9× | (29.94%) |
| FY2023 | 12.7× | 21.42% |
| FY2022 | 10.5× | (18.61%) |
| FY2021 | 12.9× | 144.97% |
| FY2020 | 5.3× | — |
| FY2019 | −31.0× | — |
| FY2018 | −40.6× | — |
| FY2017 | −0.1× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 9.1× | (11.07%) |
| Jun 2026 | 10.2× | (9.27%) |
| Mar 2026 | 11.3× | (9.94%) |
| Dec 2025 | 12.5× | 32.94% |
| 28 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| BEAM Beam Therapeutics Inc. | 9.1× |
| MBX MBX Biosciences, Inc. compare | 8.6× |
| XNCR Xencor, Inc. compare | 6.6× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 5.1× |
| RCUS Arcus Biosciences, Inc. compare | 2.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.0× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement